RSS Amplifier

Topic · biopharma · Podcasts

biopharma: podcasts

The 42 most recent episodes on this topic, about 18 hours of it.

Saves to your Listen queue, to pick up on another day or another device.

Pick anything below and it plays in the bar at the foot of the window — and keeps playing while you go on browsing the directory.

  1. Drug Fix: What FDA Commissioner Nominee Heidi Overton Will Mean For The AgencyCiteline Podcasts30:10
  2. Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And TreatmentCiteline Podcasts32:49
  3. Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDABioCentury This Week25:28
  4. Strategic Intent: The Rise Of Mid-Cap DealmakersCiteline Podcasts16:25
  5. Building The GLP-1 Companion Category, With Beverley Law And Martina GrippCiteline Podcasts47:40
  6. Drug Fix: Understanding The PDUFA VIII Revenue Cut And GDUFA IV Name ChangeCiteline Podcasts28:42
  7. The State of Play in Biotech and the Decisions Shaping the IndustryCiteline Podcasts1:00:58
  8. Strategic Intent: First-in-class, two markets: Annexon’s GBS and GA StrategiesCiteline Podcasts33:35
  9. Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOsBioCentury This Week31:43
  10. Drug Fix: Regulatory Nationalism And US FDA’s IND ReformsCiteline Podcasts24:29
  11. Proof of Concept - AI in Drug DiscoveryCiteline Podcasts46:43
  12. Digital Health Roundup: CE Mark For Vision-Restoring Implant, AI Chatbot Rules, MS DealCiteline Podcasts11:52
  13. Podcast: China's Evolving Role in Global Clinical DevelopmentCiteline Podcasts17:39
  14. Off-Patent, On Record: View Through The Journalist's Lens With Generics Bulletin's Dave WallaceCiteline Podcasts24:16
  15. Ep. 380 - AZ-BMS rumors, Replimune, psychedelicsBioCentury This Week32:25
  16. Lance Baldo: CEO of Beacon TherapeuticsBioBoss26:10Notes
  17. Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecardBioCentury This Week34:09
  18. Summer Rhythm: Getting Ready for FallConnecting the Dots5:51Notes
  19. Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen dataBioCentury This Week42:07
  20. Ep. 377 - Trends in life sciences talent with CBRE's Ian AndersonBioCentury This Week29:16
  21. Ep. 376 - M&A momentum: 3Q public markets previewBioCentury This Week33:01
  22. Ep. 375 - Novartis' ADC gambit & regulation as catalyst for U.K. biotechBioCentury This Week33:44
  23. Ep. 374 - Parkinson's deep dive & FDA trial reformsBioCentury This Week34:14
  24. Shaun Bagai: CEO of RenovoRXBioBoss33:52Notes
  25. Ep. 373 - AbbVie M&A, FDA reversals, a CAR T firstBioCentury This Week30:10
  26. The Identity Crisis at the Heart of Medical AffairsConnecting the Dots8:32Notes
  27. The Human Role in Launch ReadinessConnecting the Dots8:03Notes
  28. Hyung Heon Kim: CEO of MetaViaBioBoss32:28Notes
  29. Process Unleashes InnovationConnecting the Dots8:04Notes
  30. David Southwell: CEO of Volastra TherapeuticsBioBoss31:26Notes
  31. Medical Affairs Today – A discussion with two expertsConnecting the Dots27:39Notes
  32. The Right Forum, at the Right TimeConnecting the Dots6:42Notes
  33. Stacy Lindborg: CEO of ImunonBioBoss33:40Notes
  34. Welcome to Season 8 of BioBossBioBoss1:22Notes
  35. 100 Dots Connected: Reflecting on Eight Years of ConversationsConnecting the Dots9:47Notes
  36. Michael Cloonan: CEO of Sionna TherapeuticsBioBoss44:22Notes
  37. Erik van den Berg: CEO of Memo TherapeuticsBioBoss30:59Notes
  38. Bruce Leuchter: CEO of Neurvati NeurosciencesBioBoss46:15Notes
  39. Connecting in a Volatile Job MarketConnecting the Dots9:55Notes
  40. Todd Harris: CEO of Tyra BiosciencesBioBoss29:13Notes
  41. Building Credibility as a New LeaderConnecting the Dots6:24Notes
  42. BIO and Boston: The Global Stage and HLYBConnecting the Dots6:35Notes